Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia.
Shustik
C
C
Turner
A R
AR
Desjardins
P
P
Fernandez
L
L
Rubin
S
S
Larratt
L
L
Duncan
A M V
AM
Rizi
D
D
Sadura
A
A
Shepherd
L
L
Li
D
D
Rassenti
L
L
Kipps
T
T
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D007135:Immunoglobulin Variable Region / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D009154:Mutation; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000235:genetics
D000970:Antineoplastic Agents; D007143:Immunoglobulin Heavy Chains; D007135:Immunoglobulin Variable Region; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human; D014740:Vidarabine; C024352:fludarabine